<?xml version='1.0' encoding='utf-8'?>
<document id="22313038"><sentence text="Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4."><entity charOffset="48-58" id="DDI-PubMed.22313038.s1.e0" text="famotidine" /><entity charOffset="66-77" id="DDI-PubMed.22313038.s1.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22313038.s1.e0" e2="DDI-PubMed.22313038.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22313038.s1.e0" e2="DDI-PubMed.22313038.s1.e1" /></sentence><sentence text="Inhibitory potential of proton pump inhibitors (PPIs) and famotidine, an H(2) receptor antagonist, on the metabolic activation of clopidogrel was evaluated using recombinant CYP2B6, CYP2C19 and CYP3A4"><entity charOffset="58-68" id="DDI-PubMed.22313038.s2.e0" text="famotidine" /><entity charOffset="130-141" id="DDI-PubMed.22313038.s2.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22313038.s2.e0" e2="DDI-PubMed.22313038.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22313038.s2.e0" e2="DDI-PubMed.22313038.s2.e1" /></sentence><sentence text=" Formation of the active metabolite from an intermediate metabolite, 2-oxo-clopidogrel, was investigated by liquid chromatography-tandem mass spectrometry and three peaks corresponding to the pharmacologically active metabolite and its stereoisomers were detected"><entity charOffset="69-86" id="DDI-PubMed.22313038.s3.e0" text="2-oxo-clopidogrel" /></sentence><sentence text=" Omeprazole potently inhibited clopidogrel activation by CYP2C19 with an IC(50) of 12"><entity charOffset="1-11" id="DDI-PubMed.22313038.s4.e0" text="Omeprazole" /><entity charOffset="31-42" id="DDI-PubMed.22313038.s4.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22313038.s4.e0" e2="DDI-PubMed.22313038.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22313038.s4.e0" e2="DDI-PubMed.22313038.s4.e1" /></sentence><sentence text="8 μmol/L and more weakly inhibited that by CYP2B6 and CYP3A4" /><sentence text=" IC(50) of omeprazole for CYP2C19 and CYP3A4 was decreased about two- and three-fold, respectively, by 30-min preincubation with NADPH"><entity charOffset="11-21" id="DDI-PubMed.22313038.s6.e0" text="omeprazole" /><entity charOffset="129-134" id="DDI-PubMed.22313038.s6.e1" text="NADPH" /><pair ddi="false" e1="DDI-PubMed.22313038.s6.e0" e2="DDI-PubMed.22313038.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22313038.s6.e0" e2="DDI-PubMed.22313038.s6.e1" /></sentence><sentence text=" Lansoprazole, esomeprazole, pantoprazole, rabeprazole and rabeprazole thioether, a major metabolite, also inhibited metabolic activation by CYP2C19, with an IC(50) of 4"><entity charOffset="1-13" id="DDI-PubMed.22313038.s7.e0" text="Lansoprazole" /><entity charOffset="15-27" id="DDI-PubMed.22313038.s7.e1" text="esomeprazole" /><entity charOffset="29-41" id="DDI-PubMed.22313038.s7.e2" text="pantoprazole" /><entity charOffset="43-54" id="DDI-PubMed.22313038.s7.e3" text="rabeprazole" /><entity charOffset="59-80" id="DDI-PubMed.22313038.s7.e4" text="rabeprazole thioether" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e0" e2="DDI-PubMed.22313038.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e0" e2="DDI-PubMed.22313038.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e0" e2="DDI-PubMed.22313038.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e0" e2="DDI-PubMed.22313038.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e0" e2="DDI-PubMed.22313038.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e1" e2="DDI-PubMed.22313038.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e1" e2="DDI-PubMed.22313038.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e1" e2="DDI-PubMed.22313038.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e1" e2="DDI-PubMed.22313038.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e2" e2="DDI-PubMed.22313038.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e2" e2="DDI-PubMed.22313038.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e2" e2="DDI-PubMed.22313038.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e3" e2="DDI-PubMed.22313038.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22313038.s7.e3" e2="DDI-PubMed.22313038.s7.e4" /></sentence><sentence text="3, 8" /><sentence text="9, 48" /><sentence text="3, 36" /><sentence text="2 and 30" /><sentence text="5 μmol/L, respectively" /><sentence text=" In contrast, famotidine showed no more than 20% inhibition of clopidogrel activation by CYP2B6, CYP2C19 and CYP3A4 at up to 100 μmol/L and had no time-dependent CYP2C19 and CYP3A4 inhibition"><entity charOffset="14-24" id="DDI-PubMed.22313038.s13.e0" text="famotidine" /><entity charOffset="63-74" id="DDI-PubMed.22313038.s13.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22313038.s13.e0" e2="DDI-PubMed.22313038.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22313038.s13.e0" e2="DDI-PubMed.22313038.s13.e1" /></sentence><sentence text=" These results provide direct evidence that PPIs inhibit clopidogrel metabolic activation and suggest that CYP2C19 inhibition is the main cause of drug-drug interaction between clopidogrel and omeprazole"><entity charOffset="57-68" id="DDI-PubMed.22313038.s14.e0" text="clopidogrel" /><entity charOffset="177-188" id="DDI-PubMed.22313038.s14.e1" text="clopidogrel" /><entity charOffset="193-203" id="DDI-PubMed.22313038.s14.e2" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.22313038.s14.e0" e2="DDI-PubMed.22313038.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22313038.s14.e0" e2="DDI-PubMed.22313038.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22313038.s14.e0" e2="DDI-PubMed.22313038.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22313038.s14.e1" e2="DDI-PubMed.22313038.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22313038.s14.e1" e2="DDI-PubMed.22313038.s14.e2" /></sentence><sentence text=" Famotidine is considered as a safe anti-acid agent for patients taking clopidogrel"><entity charOffset="1-11" id="DDI-PubMed.22313038.s15.e0" text="Famotidine" /><entity charOffset="72-83" id="DDI-PubMed.22313038.s15.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22313038.s15.e0" e2="DDI-PubMed.22313038.s15.e0" /><pair ddi="false" e1="DDI-PubMed.22313038.s15.e0" e2="DDI-PubMed.22313038.s15.e1" /></sentence><sentence text="" /></document>